Zhi-Guo Luo1, Qian Wang1, Wei Peng1, Xi-Chun Hu1, Xiao-Nan Hong1. 1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Abstract
BACKGROUND: For patients with anthracycline-resistant metastatic angiosarcoma, there is currently no available standard for second-line therapy, and a need exists for novel effective regimens to improve response rates. CASE REPORT: We report here on a case of a primary angiosarcoma of both breasts in a 34-year-old woman presenting with lung metastases. Upon completion of 3 cycles of the MAID regimen (mesna, adriamycin, ifosfamide, dacarbazine), computed tomography showed disease progression. Subsequently, a second-line chemotherapy was started using the GVP regimen (gemcitabine, vincristine, cisplatin). Complete response of the lung metastases was achieved after 6 cycles of treatment. CONCLUSION: In the absence of an effective therapy among patients with anthracycline-resistant metastatic breast angiosarcoma, a GVP chemotherapy regimen can be performed as a selective option.
BACKGROUND: For patients with anthracycline-resistant metastatic angiosarcoma, there is currently no available standard for second-line therapy, and a need exists for novel effective regimens to improve response rates. CASE REPORT: We report here on a case of a primary angiosarcoma of both breasts in a 34-year-old woman presenting with lung metastases. Upon completion of 3 cycles of the MAID regimen (mesna, adriamycin, ifosfamide, dacarbazine), computed tomography showed disease progression. Subsequently, a second-line chemotherapy was started using the GVP regimen (gemcitabine, vincristine, cisplatin). Complete response of the lung metastases was achieved after 6 cycles of treatment. CONCLUSION: In the absence of an effective therapy among patients with anthracycline-resistant metastatic breast angiosarcoma, a GVP chemotherapy regimen can be performed as a selective option.
Entities:
Keywords:
Angiosarcoma; Breast neoplasm; Chemotherapy; Cisplatin; Gemcitabine; Lung metastases; Vincristine
Authors: Alberto Luini; Giovanna Gatti; Jack Diaz; Edoardo Botteri; Eliegina Oliveira; Rafaela Cecilio Sahium de Almeida; Paolo Veronesi; Mattia Intra; Gianmatteo Pagani; Paola Naninato; Giuseppe Viale Journal: Breast Cancer Res Treat Date: 2006-11-18 Impact factor: 4.872
Authors: M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Anna Minchom; Robin L Jones; Cyril Fisher; Omar Al-Muderis; Sue Ashley; Michelle Scurr; Vasilios Karavasilis; Ian R Judson Journal: Sarcoma Date: 2010-05-20
Authors: Taimur Sher; Bryan T Hennessy; Vicente Valero; Krisitine Broglio; Wendy A Woodward; Jonathan Trent; Kelly K Hunt; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Cancer Date: 2007-07-01 Impact factor: 6.860